Literature DB >> 12436111

Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis.

Manabu Ato1, Simona Stäger, Christian R Engwerda, Paul M Kaye.   

Abstract

Interaction between dendritic cells (DCs) and T cells is essential for the generation of cell-mediated immunity. Here we show that DCs from mice with chronic Leishmania donovani infection fail to migrate from the marginal zone to the periarteriolar region of the spleen. Stromal cells were fewer, which was associated with loss of CCL21 and CCL19 expression. The residual stromal cells and endothelium produced sufficient CCL21 to direct the migration of DCs transferred from naïve mice. However, DCs from infected mice had impaired migration both in naïve recipients and in vitro, in response to CCL21 and CCL19. Defective localization was attributable to tumor necrosis factor-alpha-dependent, interleukin 10-mediated inhibition of CCR7 expression. Effective immunotherapy was achieved with CCR7-expressing DCs, without the need to identify protective Leishmania antigens. Thus defective DC migration plays a major role in the pathogenesis of this disease and the immunosuppression is mediated, at least in part, through the spatial segregation of DCs and T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12436111     DOI: 10.1038/ni861

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  69 in total

Review 1.  Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances.

Authors:  Gwendalyn J Randolph; Guzman Sanchez-Schmitz; Veronique Angeli
Journal:  Springer Semin Immunopathol       Date:  2005-01

Review 2.  Regulation of antigen uptake, migration, and lifespan of dendritic cell by Toll-like receptors.

Authors:  Ivan Zanoni; Francesca Granucci
Journal:  J Mol Med (Berl)       Date:  2010-06-18       Impact factor: 4.599

3.  [Functional splenic pathology and differential diagnosis in splenectomy].

Authors:  A Marx; M Hartmann; A Zettl; H K Müller-Hermelink; T Rüdiger
Journal:  Pathologe       Date:  2008-03       Impact factor: 1.011

Review 4.  Modulation of dendritic cell responses by parasites: a common strategy to survive.

Authors:  César A Terrazas; Luis I Terrazas; Lorena Gómez-García
Journal:  J Biomed Biotechnol       Date:  2010-02-24

5.  Mechanisms of immune evasion in leishmaniasis.

Authors:  Gaurav Gupta; Steve Oghumu; Abhay R Satoskar
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

6.  Temporal regulation of interleukin-12p70 (IL-12p70) and IL-12-related cytokines in splenic dendritic cell subsets during Leishmania donovani infection.

Authors:  Asher Maroof; Paul M Kaye
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

7.  Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Simona Stäger; Clare E Alexander; Amanda C Stanley; Paul M Kaye
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

8.  Deficiency of lymph node-resident dendritic cells (DCs) and dysregulation of DC chemoattractants in a malnourished mouse model of Leishmania donovani infection.

Authors:  Marwa K Ibrahim; Jeffrey L Barnes; E Yaneth Osorio; Gregory M Anstead; Fabio Jimenez; John J Osterholzer; Bruno L Travi; Seema S Ahuja; A Clinton White; Peter C Melby
Journal:  Infect Immun       Date:  2014-05-12       Impact factor: 3.441

9.  Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation.

Authors:  Arun Kumar Haldar; Vinod Yadav; Eshu Singhal; Kamlesh Kumar Bisht; Alpana Singh; Suniti Bhaumik; Rajatava Basu; Pradip Sen; Syamal Roy
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

Review 10.  Modulation of dendritic cell function by Leishmania parasites.

Authors:  Lynn Soong
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.